Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 양철수 | - |
dc.date.accessioned | 2024-04-11T23:45:55Z | - |
dc.date.available | 2024-04-11T23:45:55Z | - |
dc.date.issued | 2024-02-01 | - |
dc.identifier.citation | EXPERIMENTAL AND MOLECULAR MEDICINE | en_US |
dc.identifier.issn | 2092-6413 | en_US |
dc.identifier.issn | 1226-3613 | en_US |
dc.identifier.uri | https://www.nature.com/articles/s12276-024-01165-7 | en_US |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/189694 | - |
dc.description.abstract | Immune-mediated inflammatory diseases are various groups of conditions that result in immune system disorders and increased cancer risk. Despite the identification of causative cytokines and pathways, current clinical treatment for immune-mediated inflammatory diseases is limited. In addition, immune-mediated inflammatory disease treatment can increase the risk of cancer. Several previous studies have demonstrated that Toxoplasma gondii manipulates the immune response by inhibiting or stimulating cytokines, suggesting the potential for controlling and maintaining a balanced immune system. Additionally, T. gondii also has the unique characteristic of being a so-called "Trojan horse" bacterium that can be used as a drug delivery system to treat regions that have been resistant to previous drug delivery therapies. In this study, we reviewed the potential of T. gondii in drug development and as a delivery system through current research on inflammation-regulating mechanisms in immune-mediated inflammatory diseases. | en_US |
dc.description.sponsorship | This work was supported by a National Research Foundation of Korea grant funded by the Korean government (MSIP) (grant no. 2019R1I1A2A01064237 and 2021R1A4A5032463) and by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI22C0884). C.Y. was supported by the research fund of Hanyang University (HY-2023-0536). | en_US |
dc.language | en_US | en_US |
dc.publisher | SPRINGERNATURE | en_US |
dc.relation.ispartofseries | v. 56, NO 2;289-300 | - |
dc.title | Exploring the potential of Toxoplasma gondii in drug development and as a delivery system | en_US |
dc.type | Article | en_US |
dc.relation.no | 2 | - |
dc.relation.volume | 56 | - |
dc.identifier.doi | 10.1038/s12276-024-01165-7 | en_US |
dc.relation.page | 289-300 | - |
dc.relation.journal | EXPERIMENTAL AND MOLECULAR MEDICINE | - |
dc.contributor.googleauthor | Yoon, Chanjin | - |
dc.contributor.googleauthor | Ham, Yu Seong | - |
dc.contributor.googleauthor | Gil, Woo Jin | - |
dc.contributor.googleauthor | Yang, Chul-Su | - |
dc.relation.code | 2024008719 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF SCIENCE AND CONVERGENCE TECHNOLOGY[E] | - |
dc.sector.department | DEPARTMENT OF MEDICINAL AND LIFE SCIENCES | - |
dc.identifier.pid | chulsuyang | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.